4.7 Article

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

Journal

NPJ PRECISION ONCOLOGY
Volume 4, Issue 1, Pages -

Publisher

NATURE RESEARCH
DOI: 10.1038/s41698-020-0112-3

Keywords

-

Categories

Funding

  1. National Key R&D Program of China [2016YFC0905500, 2016YFC0905503]
  2. Chinese National Natural Science Foundation [81872499, 81772476]
  3. Science and Technology Program of Guangdong [2017B020227001]
  4. Science and Technology Program of Guangzhou [201607020031, 201704020072]

Ask authors/readers for more resources

Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available